|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:approvalYear
|
1984
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N07BB04
|
|
gptkbp:bioavailability
|
5-40% (oral)
|
|
gptkbp:brand
|
gptkb:Vivitrol
gptkb:Depade
gptkb:ReVia
|
|
gptkbp:CASNumber
|
16590-41-3
|
|
gptkbp:chemicalFormula
|
C20H23NO4
|
|
gptkbp:compatibleWith
|
controlled substance (US)
|
|
gptkbp:contraindication
|
liver failure
acute hepatitis
|
|
gptkbp:developedBy
|
gptkb:United_States
|
|
gptkbp:discoveredBy
|
gptkb:Endo_Laboratories
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1963
|
|
gptkbp:hasEnantiomer
|
gptkb:levallorphan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
naltrexone
|
|
gptkbp:interactsWith
|
gptkb:opioid_analgesics
gptkb:disulfiram
|
|
gptkbp:KEGGID
|
D08202
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks opioid receptors
|
|
gptkbp:MeSH_ID
|
D009373
|
|
gptkbp:metabolism
|
gptkb:6-beta-naltrexol
liver
|
|
gptkbp:molecularWeight
|
341.4 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
21%
|
|
gptkbp:PubChem_CID
|
5360515
4514932
CHEMBL1536
DB00704
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
|
|
gptkbp:synonym
|
N-cyclopropylmethyl-14-hydroxynormorphinone
|
|
gptkbp:UNII
|
2S7953Q994
|
|
gptkbp:usedFor
|
alcohol dependence
opioid dependence
|
|
gptkbp:bfsParent
|
gptkb:Thebaine
gptkb:opioid
gptkb:Mysimba
|
|
gptkbp:bfsLayer
|
6
|